Proapoptotic and Antiapoptotic Proteins of the Bcl-2 Family Regulate Sensitivity of Pancreatic Cancer Cells Toward Gemcitabine and T-Cell–mediated Cytotoxicity. Issue 3 (April 2015)
- Record Type:
- Journal Article
- Title:
- Proapoptotic and Antiapoptotic Proteins of the Bcl-2 Family Regulate Sensitivity of Pancreatic Cancer Cells Toward Gemcitabine and T-Cell–mediated Cytotoxicity. Issue 3 (April 2015)
- Main Title:
- Proapoptotic and Antiapoptotic Proteins of the Bcl-2 Family Regulate Sensitivity of Pancreatic Cancer Cells Toward Gemcitabine and T-Cell–mediated Cytotoxicity
- Authors:
- Bauer, Christian
Hees, Claudia
Sterzik, Alexander
Bauernfeind, Franz
Mak'Anyengo, Rachel
Duewell, Peter
Lehr, Hans-Anton
Noessner, Elfriede
Wank, Rudolf
Trauzold, Anna
Endres, Stefan
Dauer, Marc
Schnurr, Max - Abstract:
- Abstract : Sensitivity of carcinoma cells towards gemcitabine (Gem) has been linked to mitochondrial apoptotic proteins. Recently, we described synergistic efficacy of Gem-based chemoimmunotherapy and a dendritic cell (DC) tumor vaccine in a murine pancreatic carcinoma model. Here, we investigated the role of the mitochondrial proteins Bcl-2, Bcl-xL, and Bax for sensitization of pancreatic carcinoma cells toward T-cell–mediated cytotoxicity alone and in combination with Gem. Bcl-2 expression was silenced by siRNA in Panc02 pancreatic cancer cells expressing the model antigen ovalbumin (PancOVA). Tumor cells were treated with Gem and/or siRNA, and cytotoxicity induced by OVA-specific cytotoxic T lymphocytes (CTL) from OT-1 mice was assessed. Gem-induced and T-cell–induced cytotoxicity was also studied in human Colo357 pancreatic cancer cell lines overexpressing Bax or Bcl-xL. Apoptosis induction by Fas-activating antibody was measured by Annexin V staining. The in vivo capacity of Bcl-2 siRNA to augment CTL efficacy induced by DC vaccinations was assessed in C57BL/6 mice bearing PancOVA tumors. PancOVA cells treated with Bcl-2 siRNA were sensitized towards both Gem and T-cell–mediated killing; combination therapy exhibited an additive effect. Bax overexpression sensitized Colo357 cells to both Gem-mediated and T-cell–mediated cytotoxicity, whereas Bcl-xL overexpression was inhibitory. Combining Bcl-2 silencing with DC therapy improved tumor control in the PancOVA model inAbstract : Sensitivity of carcinoma cells towards gemcitabine (Gem) has been linked to mitochondrial apoptotic proteins. Recently, we described synergistic efficacy of Gem-based chemoimmunotherapy and a dendritic cell (DC) tumor vaccine in a murine pancreatic carcinoma model. Here, we investigated the role of the mitochondrial proteins Bcl-2, Bcl-xL, and Bax for sensitization of pancreatic carcinoma cells toward T-cell–mediated cytotoxicity alone and in combination with Gem. Bcl-2 expression was silenced by siRNA in Panc02 pancreatic cancer cells expressing the model antigen ovalbumin (PancOVA). Tumor cells were treated with Gem and/or siRNA, and cytotoxicity induced by OVA-specific cytotoxic T lymphocytes (CTL) from OT-1 mice was assessed. Gem-induced and T-cell–induced cytotoxicity was also studied in human Colo357 pancreatic cancer cell lines overexpressing Bax or Bcl-xL. Apoptosis induction by Fas-activating antibody was measured by Annexin V staining. The in vivo capacity of Bcl-2 siRNA to augment CTL efficacy induced by DC vaccinations was assessed in C57BL/6 mice bearing PancOVA tumors. PancOVA cells treated with Bcl-2 siRNA were sensitized towards both Gem and T-cell–mediated killing; combination therapy exhibited an additive effect. Bax overexpression sensitized Colo357 cells to both Gem-mediated and T-cell–mediated cytotoxicity, whereas Bcl-xL overexpression was inhibitory. Combining Bcl-2 silencing with DC therapy improved tumor control in the PancOVA model in vivo without affecting the number of tumor-reactive CTL. In conclusion, expression of Bcl-2, Bcl-xL, and Bax in pancreatic tumor cells determines sensitivity towards both Gem-mediated and CTL-mediated toxicity. Bcl-2 silencing could be exploited therapeutically in tumor vaccine approaches. … (more)
- Is Part Of:
- Journal of immunotherapy. Volume 38:Issue 3(2015:Apr.)
- Journal:
- Journal of immunotherapy
- Issue:
- Volume 38:Issue 3(2015:Apr.)
- Issue Display:
- Volume 38, Issue 3 (2015)
- Year:
- 2015
- Volume:
- 38
- Issue:
- 3
- Issue Sort Value:
- 2015-0038-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2015-04
- Subjects:
- vaccination -- siRNA -- Bcl-2 -- mitochondrial proteins -- dendritic cells -- pancreatic carcinoma -- chemotherapy -- gemcitabine
Immunotherapy -- Periodicals
Immunotherapy -- Periodicals
Neoplasms -- therapy -- Periodicals
Electronic journals
Electronic journals
615.37 - Journal URLs:
- http://www.immunotherapy-journal.com/ ↗
http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&PAGE=toc&D=ovft&AN=00002371-000000000-00000 ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/CJI.0000000000000073 ↗
- Languages:
- English
- ISSNs:
- 1524-9557
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5005.040000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 4537.xml